{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:41:56Z","timestamp":1782409316087,"version":"3.54.5"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007606","name":"Aarhus University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02282-x","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:50:30Z","timestamp":1769683830000},"page":"287-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developments and Challenges in Treating Rheumatoid Arthritis-Related Interstitial Lung Disease: From Pathogenesis to Treatment Opportunities"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-6421","authenticated-orcid":false,"given":"Marco","family":"Sebastiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-5947","authenticated-orcid":false,"given":"Fabrizio","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-6963","authenticated-orcid":false,"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2282_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet Lond Engl. 2016;388:2023\u201338.","journal-title":"Lancet Lond Engl"},{"key":"2282_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/1744666X.2021.1905524","volume":"17","author":"A Manfredi","year":"2021","unstructured":"Manfredi A, Cassone G, Luppi F, Atienza-Mateo B, Cavazza A, Sverzellati N, et al. Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol. 2021;17:485\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"2282_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/BOR.0b013e32835f693f","volume":"25","author":"C Turesson","year":"2013","unstructured":"Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:360\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"2282_CR4","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, L\u00f8kke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2282_CR5","first-page":"3","volume":"69","author":"NJ Minaur","year":"2004","unstructured":"Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40\u00a0years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69:3\u20138.","journal-title":"J Rheumatol"},{"key":"2282_CR6","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1513\/AnnalsATS.202102-115OC","volume":"18","author":"N Jeganathan","year":"2021","unstructured":"Jeganathan N, Nguyen E, Sathananthan M. Rheumatoid arthritis and associated interstitial lung disease: mortality rates and trends. Ann Am Thorac Soc. 2021;18:1970\u20137.","journal-title":"Ann Am Thorac Soc"},{"key":"2282_CR7","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","volume":"60","author":"CA Kelly","year":"2021","unstructured":"Kelly CA, Nisar M, Arthanari S, Carty S, Woodhead FA, Price-Forbes A, et al. Rheumatoid arthritis related interstitial lung disease\u2014improving outcomes over 25\u00a0years: a large multicentre UK study. Rheumatology. 2021;60:1882\u201390.","journal-title":"Rheumatology"},{"key":"2282_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"2282_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/acr.25348","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res. 2024;76:1051\u201369.","journal-title":"Arthritis Care Res"},{"key":"2282_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.reuma.2022.03.005","volume":"18","author":"J Narv\u00e1ez","year":"2022","unstructured":"Narv\u00e1ez J, D\u00edaz Del Campo Fontecha P, Brito Garc\u00eda N, Bonilla G, Aburto M, Castellv\u00ed I, et al. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: treatment. Reumatol Clin. 2022;18:501\u201312.","journal-title":"Reumatol Clin"},{"key":"2282_CR11","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2025.1865","author":"C Crotti","year":"2025","unstructured":"Crotti C, Ughi N, Scir\u00e8 CA, Luppi F, Atzeni F, Bosello S, et al. The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease. Reumatismo. 2025. https:\/\/doi.org\/10.4081\/reumatismo.2025.1865.","journal-title":"Reumatismo"},{"issue":"1","key":"2282_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","volume":"85","author":"KM Antoniou","year":"2026","unstructured":"Antoniou KM, Distler O, Gheorghiu A-M, Moor CC, Vikse J, Bizymi N, et al. ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease. Ann Rheum Dis. 2026;85(1)22\u201360.","journal-title":"Ann Rheum Dis"},{"key":"2282_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-0039-1685165","volume":"40","author":"J Barnett","year":"2019","unstructured":"Barnett J, Devaraj A. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med. 2019;40:159\u201372.","journal-title":"Semin Respir Crit Care Med"},{"key":"2282_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13075-024-03362-1","volume":"26","author":"Y-J Song","year":"2024","unstructured":"Song Y-J, Kim H, Cho S-K, Kim HW, Lim C, Nam E, et al. Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study. Arthritis Res Ther. 2024;26:137.","journal-title":"Arthritis Res Ther"},{"key":"2282_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12890-023-02783-z","volume":"23","author":"F Luppi","year":"2023","unstructured":"Luppi F, Manfredi A, Faverio P, Andersen MB, Bono F, Pagni F, et al. The usual interstitial pneumonia pattern in autoimmune rheumatic diseases. BMC Pulm Med. 2023;23:501.","journal-title":"BMC Pulm Med"},{"key":"2282_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041082","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone G, Manfredi A, Vacchi C, Luppi F, Coppi F, Salvarani C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9:1082.","journal-title":"J Clin Med"},{"key":"2282_CR17","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1038\/s41598-021-88734-2","volume":"11","author":"E Cano-Jim\u00e9nez","year":"2021","unstructured":"Cano-Jim\u00e9nez E, V\u00e1zquez Rodr\u00edguez T, Mart\u00edn-Robles I, Castillo Villegas D, JuanGarc\u00eda J, Bollo de Miguel E, et al. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep. 2021;11:9184.","journal-title":"Sci Rep"},{"key":"2282_CR18","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","volume":"36","author":"J Rojas-Serrano","year":"2017","unstructured":"Rojas-Serrano J, Herrera-Bringas D, P\u00e9rez-Rom\u00e1n DI, P\u00e9rez-Dorame R, Mateos-Toledo H, Mej\u00eda M. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017;36:1493\u2013500.","journal-title":"Clin Rheumatol"},{"key":"2282_CR19","volume":"2000","author":"ME Suarez-Almazor","year":"2000","unstructured":"Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2000:CD001461.","journal-title":"Cochrane Database Syst Rev"},{"key":"2282_CR20","volume":"2000","author":"ME Suarez-Almazor","year":"2000","unstructured":"Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2000:CD001157.","journal-title":"Cochrane Database Syst Rev"},{"key":"2282_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s12890-024-03287-0","volume":"24","author":"MK Cartlidge","year":"2024","unstructured":"Cartlidge MK, Brown KK, Chaudhuri N, Corte TJ, Dieud\u00e9 P, John L, et al. A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease. BMC Pulm Med. 2024;24:547.","journal-title":"BMC Pulm Med"},{"key":"2282_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/crj.70116","volume":"19","author":"AA Lewandowska","year":"2025","unstructured":"Lewandowska AA, Wa\u015bniowska D, Rybacki C, Graczyk M, Duszy\u0144ska O, Mirus-Arabik H, et al. Pulmonary complications in connective tissue disease-associated interstitial lung disease. Clin Respir J. 2025;19:e70116.","journal-title":"Clin Respir J"},{"key":"2282_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1055\/s-0039-1684020","volume":"40","author":"A Wells","year":"2019","unstructured":"Wells A, Devaraj A, Renzoni EA, Denton CP. Multidisciplinary evaluation in patients with lung disease associated with connective tissue disease. Semin Respir Crit Care Med. 2019;40:184\u201393.","journal-title":"Semin Respir Crit Care Med"},{"key":"2282_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/13543784.2024.2376567","volume":"33","author":"M Sebastiani","year":"2024","unstructured":"Sebastiani M, Manfredi A, Croci S, Faverio P, Cassone G, Vacchi C, et al. Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs. Expert Opin Investig Drugs. 2024;33:815\u201327.","journal-title":"Expert Opin Investig Drugs"},{"key":"2282_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11926-024-01155-8","volume":"26","author":"DI Sullivan","year":"2024","unstructured":"Sullivan DI, Ascherman DP. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): update on prevalence, risk factors, pathogenesis, and therapy. Curr Rheumatol Rep. 2024;26:431\u201349.","journal-title":"Curr Rheumatol Rep"},{"key":"2282_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1165\/rcmb.2020-0373PS","volume":"64","author":"A Pardo","year":"2021","unstructured":"Pardo A, Selman M. The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2021;64:163\u201372.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2282_CR27","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.3390\/ijms24032405","volume":"24","author":"G Cerro Chiang","year":"2023","unstructured":"Cerro Chiang G, Parimon T. Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): genetics, cellular pathophysiology, and biologic drivers. Int J Mol Sci. 2023;24:2405.","journal-title":"Int J Mol Sci"},{"key":"2282_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1573397115666190116102451","volume":"15","author":"EK Wu","year":"2019","unstructured":"Wu EK, Ambrosini RD, Kottmann RM, Ritchlin CT, Schwarz EM, Rahimi H. Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev. 2019;15:277\u201389.","journal-title":"Curr Rheumatol Rev"},{"key":"2282_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103056","volume":"21","author":"M Akiyama","year":"2022","unstructured":"Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022;21:103056.","journal-title":"Autoimmun Rev"},{"key":"2282_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12931-018-0864-2","volume":"19","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wang Y, Wu G, Xiong W, Gu W, Wang C-Y. Macrophages: friend or foe in idiopathic pulmonary fibrosis? Respir Res. 2018;19:170.","journal-title":"Respir Res"},{"key":"2282_CR31","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/cells12172193","volume":"12","author":"D Pokhreal","year":"2023","unstructured":"Pokhreal D, Crestani B, Helou DG. Macrophage implication in IPF: updates on immune, epigenetic, and metabolic pathways. Cells. 2023;12:2193.","journal-title":"Cells"},{"key":"2282_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557583","volume":"16","author":"JA Poole","year":"2025","unstructured":"Poole JA, Schwab A, Thiele GM, Wyatt TA, Nelson AJ, Schanze OW, et al. Lung disease in relation to unique monocyte-macrophage subpopulations induced by combined inhalant endotoxin and collagen-induced arthritis. Front Immunol. 2025;16:1557583.","journal-title":"Front Immunol"},{"key":"2282_CR33","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"MA Seibold","year":"2011","unstructured":"Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503\u201312.","journal-title":"N Engl J Med"},{"key":"2282_CR34","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"P-A Juge","year":"2018","unstructured":"Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209\u201319.","journal-title":"N Engl J Med"},{"key":"2282_CR35","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1183\/13993003.02115-2015","volume":"48","author":"R Borie","year":"2016","unstructured":"Borie R, Tab\u00e8ze L, Thabut G, Nunes H, Cottin V, Marchand-Adam S, et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J. 2016;48:1721\u201331.","journal-title":"Eur Respir J"},{"key":"2282_CR36","doi-asserted-by":"publisher","first-page":"1602314","DOI":"10.1183\/13993003.02314-2016","volume":"49","author":"P-A Juge","year":"2017","unstructured":"Juge P-A, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017;49:1602314.","journal-title":"Eur Respir J"},{"key":"2282_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41584-024-01096-7","volume":"20","author":"VL Kronzer","year":"2024","unstructured":"Kronzer VL, Sparks JA, Raychaudhuri S, Cerhan JR. Low-frequency and rare genetic variants associated with rheumatoid arthritis risk. Nat Rev Rheumatol. 2024;20:290\u2013300.","journal-title":"Nat Rev Rheumatol"},{"key":"2282_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"2282_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020407","volume":"9","author":"C Vacchi","year":"2020","unstructured":"Vacchi C, Sebastiani M, Cassone G, Cerri S, Della Casa G, Salvarani C, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J Clin Med. 2020;9:407.","journal-title":"J Clin Med"},{"key":"2282_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/03009742.2025.2503054","volume":"54","author":"C Hyldgaard","year":"2025","unstructured":"Hyldgaard C, Pedersen AR, Ellingsen T, Bendstrup E. Pulmonary function trajectories in rheumatoid arthritis-associated interstitial lung disease. Scand J Rheumatol. 2025;54:339\u201345.","journal-title":"Scand J Rheumatol"},{"key":"2282_CR41","doi-asserted-by":"publisher","first-page":"2100079","DOI":"10.1183\/13993003.00079-2021","volume":"57","author":"V Cottin","year":"2021","unstructured":"Cottin V, Bendstrup E, Bonniaud P, Nasser M, Spagnolo P, Valenzuela C, et al. The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. Eur Respir J. 2021;57:2100079.","journal-title":"Eur Respir J"},{"key":"2282_CR42","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s10067-024-07068-2","volume":"43","author":"E Park","year":"2024","unstructured":"Park E, Iqbal R, Giles JT, Bernstein EJ. Use of methotrexate and TNF inhibitors in patients with rheumatoid arthritis-associated interstitial lung disease: a survey of rheumatologists. Clin Rheumatol. 2024;43:3029\u201332.","journal-title":"Clin Rheumatol"},{"key":"2282_CR43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","volume":"66","author":"R Conway","year":"2014","unstructured":"Conway R, Low C, Coughlan RJ, O\u2019Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66:803\u201312.","journal-title":"Arthritis Rheumatol"},{"key":"2282_CR44","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology. 2019;58:1900\u20136.","journal-title":"Rheumatology"},{"key":"2282_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172:369\u201380.","journal-title":"Ann Intern Med"},{"key":"2282_CR46","doi-asserted-by":"publisher","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","volume":"57","author":"P-A Juge","year":"2021","unstructured":"Juge P-A, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57:2000337.","journal-title":"Eur Respir J"},{"key":"2282_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/rheumatology\/keaa327","volume":"60","author":"EH Ibfelt","year":"2021","unstructured":"Ibfelt EH, Jacobsen RK, Kopp TI, Cordtz RL, Jakobsen AS, Seersholm N, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology. 2021;60:346\u201352.","journal-title":"Rheumatology"},{"key":"2282_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152561","volume":"69","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, McDermott GC, Juge P-A, Chang SH, Vanni KM, Qian G, et al. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2024;69:152561.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1172\/JCI118029","volume":"96","author":"Y Miyazaki","year":"1995","unstructured":"Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995;96:250\u20139.","journal-title":"J Clin Invest"},{"key":"2282_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1006\/cyto.1997.0267","volume":"10","author":"N Sueoka","year":"1998","unstructured":"Sueoka N, Sueoka E, Miyazaki Y, Okabe S, Kurosumi M, Takayama S, et al. Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice. Cytokine. 1998;10:124\u201331.","journal-title":"Cytokine"},{"key":"2282_CR51","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","volume":"41","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256\u201364.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0835-7","volume":"17","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319.","journal-title":"Arthritis Res Ther"},{"key":"2282_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000473","volume":"3","author":"KL Druce","year":"2017","unstructured":"Druce KL, Iqbal K, Watson KD, Symmons DPM, Hyrich KL, Kelly C. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open. 2017;3:e000473.","journal-title":"RMD Open"},{"key":"2282_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103922","volume":"24","author":"A Fassio","year":"2025","unstructured":"Fassio A, Sebastiani M, Pollastri F, Cozzini F, Crotti C, Ughi N, et al. Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2025;24:103922.","journal-title":"Autoimmun Rev"},{"key":"2282_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003487","volume":"9","author":"H Yuan","year":"2023","unstructured":"Yuan H, Cui S, Yang L, Cui J, Wang X, Ding M, et al. Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. RMD Open. 2023;9:e003487.","journal-title":"RMD Open"},{"key":"2282_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152735","volume":"73","author":"H Frideres","year":"2025","unstructured":"Frideres H, Wichman CS, Dong J, Roul P, Yang Y, Baker JF, et al. Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: a propensity score-matched, active-comparator, new-user study. Semin Arthritis Rheum. 2025;73:152735.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1694-9","volume":"20","author":"G Boleto","year":"2018","unstructured":"Boleto G, Guignabert C, Pezet S, Cauvet A, Sadoine J, Tu L, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther. 2018;20:197.","journal-title":"Arthritis Res Ther"},{"key":"2282_CR58","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.yexmp.2011.09.010","volume":"91","author":"L Jim\u00e9nez-Alvarez","year":"2011","unstructured":"Jim\u00e9nez-Alvarez L, Arreola JL, Ram\u00edrez-Mart\u00ednez G, Ortiz-Quintero B, Gaxiola M, Reynoso-Robles R, et al. The effect of CTLA-4Ig, a CD28\/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis. Exp Mol Pathol. 2011;91:718\u201322.","journal-title":"Exp Mol Pathol"},{"key":"2282_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/rheumatology\/keab317","volume":"61","author":"C Fern\u00e1ndez-D\u00edaz","year":"2021","unstructured":"Fern\u00e1ndez-D\u00edaz C, Atienza-Mateo B, Casta\u00f1eda S, Melero-Gonzalez RB, Ortiz-SanJuan F, Loricera J, et al. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients. Rheumatology. 2021;61:299\u2013308.","journal-title":"Rheumatology"},{"key":"2282_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/jcm9010277","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone G, Manfredi A, Atzeni F, Venerito V, Vacchi C, Picerno V, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med. 2020;9:277.","journal-title":"J Clin Med"},{"key":"2282_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/art.43332","author":"P-C Shih","year":"2025","unstructured":"Shih P-C, Wang S-I, Wang Q-W, Wei JCC. Association of abatacept with lower mortality risk compared to rituximab in rheumatoid arthritis-associated interstitial lung disease: an emulated target trial. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43332.","journal-title":"Arthritis Rheumatol"},{"key":"2282_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102830","volume":"20","author":"EF Vicente-Rabaneda","year":"2021","unstructured":"Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Casta\u00f1eda S, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev. 2021;20:102830.","journal-title":"Autoimmun Rev"},{"key":"2282_CR63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-0044-1782218","volume":"45","author":"J Vu Pugashetti","year":"2024","unstructured":"Vu Pugashetti J, Lee JS. Overview of rheumatoid arthritis-associated interstitial lung disease and its treatment. Semin Respir Crit Care Med. 2024;45:329\u201341.","journal-title":"Semin Respir Crit Care Med"},{"key":"2282_CR64","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","volume":"163","author":"SM Matson","year":"2023","unstructured":"Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest. 2023;163:861\u20139.","journal-title":"Chest"},{"key":"2282_CR65","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","volume":"59","author":"C Vadillo","year":"2020","unstructured":"Vadillo C, Nieto MA, Romero-Bueno F, Leon L, Sanchez-Pernaute O, Rodriguez-Nieto MJ, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology. 2020;59:2099\u2013108.","journal-title":"Rheumatology"},{"key":"2282_CR66","doi-asserted-by":"publisher","first-page":"2020-8","DOI":"10.7573\/dic.2020-8-7","volume":"10","author":"C Vacchi","year":"2021","unstructured":"Vacchi C, Manfredi A, Cassone G, Erre GL, Salvarani C, Sebastiani M. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context. 2021;10:2020-8\u20132027.","journal-title":"Drugs Context"},{"key":"2282_CR67","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.3390\/jcm9103070","volume":"9","author":"B Atienza-Mateo","year":"2020","unstructured":"Atienza-Mateo B, Remuzgo-Mart\u00ednez S, Prieto-Pe\u00f1a D, Mora Cuesta VM, Iturbe-Fern\u00e1ndez D, Llorca J, et al. Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review. J Clin Med. 2020;9:3070.","journal-title":"J Clin Med"},{"key":"2282_CR68","doi-asserted-by":"crossref","unstructured":"Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5:178ra40.","DOI":"10.1126\/scitranslmed.3005580"},{"key":"2282_CR69","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/path.4359","volume":"233","author":"A Chrysanthopoulou","year":"2014","unstructured":"Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arelaki S, Mikroulis D, Konstantinidis T, et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J Pathol. 2014;233:294\u2013307.","journal-title":"J Pathol"},{"key":"2282_CR70","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/art.41798","volume":"73","author":"H Numajiri","year":"2021","unstructured":"Numajiri H, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, et al. B cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis. Arthritis Rheumatol. 2021;73:2086\u201395.","journal-title":"Arthritis Rheumatol"},{"key":"2282_CR71","doi-asserted-by":"publisher","first-page":"317","DOI":"10.46497\/ArchRheumatol.2024.10199","volume":"39","author":"T Krishna Boppana","year":"2024","unstructured":"Krishna Boppana T, Mittal S, Madan K, Mohan A, Hadda V, Guleria R. Rituximab for rheumatoid arthritis-related interstitial lung disease: a systematic review and meta-analysis. Arch Rheumatol. 2024;39:317\u201329.","journal-title":"Arch Rheumatol"},{"key":"2282_CR72","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","volume":"50","author":"J Narv\u00e1ez","year":"2020","unstructured":"Narv\u00e1ez J, Robles-P\u00e9rez A, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Ya\u00f1ez MA, et al. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Semin Arthritis Rheum. 2020;50:902\u201310.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR73","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","volume":"56","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10\u00a0years\u2019 experience at a single centre. Rheumatology. 2017;56:1348\u201357.","journal-title":"Rheumatology"},{"key":"2282_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik E, Montazeri Aliabadi H. \u201cDo we know jack\u201d about JAK? A closer look at JAK\/STAT signaling pathway. Front Oncol. 2018;8:287.","journal-title":"Front Oncol"},{"key":"2282_CR75","first-page":"442","volume":"10","author":"X Ma","year":"2013","unstructured":"Ma X, Chen R, Liu X, Xie J, Si K, Duan L. Effects of matrine on JAK-STAT signaling transduction pathways in bleomycin-induced pulmonary fibrosis. Afr J Tradit Complement Altern Med AJTCAM. 2013;10:442\u20138.","journal-title":"Afr J Tradit Complement Altern Med AJTCAM"},{"key":"2282_CR76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","volume":"19","author":"J Milara","year":"2018","unstructured":"Milara J, Hernandez G, Ballester B, Morell A, Roger I, Montero P, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19:24.","journal-title":"Respir Res"},{"key":"2282_CR77","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101436R","volume":"36","author":"S Wang","year":"2022","unstructured":"Wang S, Liu M, Li X, Zhang J, Wang F, Zhang C, et al. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB J. 2022;36:e22336.","journal-title":"FASEB J"},{"key":"2282_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126211","volume":"22","author":"P Montero","year":"2021","unstructured":"Montero P, Milara J, Roger I, Cortijo J. Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22:6211.","journal-title":"Int J Mol Sci"},{"key":"2282_CR79","first-page":"129","volume":"30","author":"M Pedroza","year":"2016","unstructured":"Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J Off Publ Fed Am Soc Exp Biol. 2016;30:129\u201340.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"2282_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109044","volume":"110","author":"Y Liu","year":"2022","unstructured":"Liu Y, Hu M, Fan G, Xing N, Zhang R. Effect of baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6. Int Immunopharmacol. 2022;110:109044.","journal-title":"Int Immunopharmacol"},{"key":"2282_CR81","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/jcm12030957","volume":"12","author":"V Venerito","year":"2023","unstructured":"Venerito V, Manfredi A, Carletto A, Gentileschi S, Atzeni F, Guiducci S, et al. Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study. J Clin Med. 2023;12:957.","journal-title":"J Clin Med"},{"key":"2282_CR82","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","volume":"30","author":"M Tardella","year":"2022","unstructured":"Tardella M, Di Carlo M, Carotti M, Ceccarelli L, Giovagnoni A, Salaffi F. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology. 2022;30:705\u201312.","journal-title":"Inflammopharmacology"},{"issue":"10","key":"2282_CR83","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1093\/rheumatology\/keaf314","volume":"64","author":"A Serrano-Combarro","year":"2025","unstructured":"Serrano-Combarro A, Atienza-Mateo B, Mart\u00edn-Guti\u00e9rrez A, Loarce Martos J, Dubuc CAE, Pastor Mena M, et al. Baricitinib in rheumatoid arthritis-interstitial lung disease: national multicenter study of 72 patients and literature review. Rheumatology (Oxford) 2025;64(10):5471\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"2282_CR84","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.resinv.2023.02.007","volume":"61","author":"T Mochizuki","year":"2023","unstructured":"Mochizuki T, Yano K, Ikari K, Okazaki K. Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1\u00a0year. Respir Investig. 2023;61:359\u201363.","journal-title":"Respir Investig"},{"key":"2282_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103636","volume":"23","author":"J Narv\u00e1ez","year":"2024","unstructured":"Narv\u00e1ez J, Aguilar-Coll M, Roig-Kim M, Maym\u00f3-Paituvi P, Palacios-Olid J, Nolla JM, et al. Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2024;23:103636.","journal-title":"Autoimmun Rev"},{"key":"2282_CR86","first-page":"1960","volume":"59","author":"Y Nishii","year":"2023","unstructured":"Nishii Y, Okamoto M, Zaizen Y, Kojima T, Nouno T, Naitou-Nishida Y, et al. Successful treatment of a patient with drug-refractory rheumatoid arthritis-associated interstitial lung disease with upadacitinib: a case report. Med Kaunas Lith. 2023;59:1960.","journal-title":"Med Kaunas Lith"},{"key":"2282_CR87","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70012","volume":"136","author":"Y Lv","year":"2025","unstructured":"Lv Y, Zhang G, Kong D, Jiang W. Filgotinib improves experimental pulmonary fibrosis by modulating JAK1\/STAT3\/SOCS3\/IL-17A signalling. Basic Clin Pharmacol Toxicol. 2025;136:e70012.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2282_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.70023","volume":"12","author":"A Sunaga","year":"2024","unstructured":"Sunaga A, Inoue T. Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: a case report on janus kinase 1 inhibition. Respirol Case Rep. 2024;12:e70023.","journal-title":"Respirol Case Rep"},{"key":"2282_CR89","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"2282_CR90","doi-asserted-by":"publisher","first-page":"152636","DOI":"10.1016\/j.semarthrit.2025.152636","volume":"71","author":"P-C Shih","year":"2025","unstructured":"Shih P-C, Zou Q-H, Lai C-C, Wang S-I, Huang X-Y, Wei JCC. Mortality and medical utilization in rheumatoid arthritis associated interstitial lung disease: a real-world, large-scale retrospective study comparing Janus kinase inhibitors and tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2025;71:152636.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136160","volume":"10","author":"C Aravena","year":"2015","unstructured":"Aravena C, Labarca G, Venegas C, Arenas A, Rada G. Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0136160.","journal-title":"PLoS ONE"},{"key":"2282_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06678-7","volume":"12","author":"K Tsoyi","year":"2022","unstructured":"Tsoyi K, Esposito AJ, Sun B, Bowen RG, Xiong K, Poli F, et al. Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts. Sci Rep. 2022;12:2847.","journal-title":"Sci Rep"},{"key":"2282_CR93","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"key":"2282_CR94","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8:963\u201374.","journal-title":"Lancet Respir Med"},{"key":"2282_CR95","first-page":"451","volume":"43","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Akiyama M, Kaneko Y. Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review. Clin Exp Rheumatol. 2025;43:451\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"2282_CR96","first-page":"127","volume":"16","author":"N Otsuji","year":"2024","unstructured":"Otsuji N, Sugiyama K, Owada T, Arifuku H, Koyama K, Hirata H, et al. Safety of tocilizumab on rheumatoid arthritis in patients with interstitial lung disease. Open Access Rheumatol Res Rev. 2024;16:127\u201335.","journal-title":"Open Access Rheumatol Res Rev."},{"key":"2282_CR97","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/imj.14670","volume":"50","author":"A Manfredi","year":"2020","unstructured":"Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J. 2020;50:1085\u201390.","journal-title":"Intern Med J"},{"key":"2282_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103668","volume":"23","author":"F Luppi","year":"2024","unstructured":"Luppi F, Manfredi A, Faverio P, Franco G, Salvarani C, Bendstrup E, et al. Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: more questions than answers. Autoimmun Rev. 2024;23:103668.","journal-title":"Autoimmun Rev"},{"key":"2282_CR99","first-page":"542","volume":"35","author":"M Sebastiani","year":"2017","unstructured":"Sebastiani M, Manfredi A, Cassone G, Sandri G, Cerri S, Ferri C. Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients. Clin Exp Rheumatol. 2017;35:542.","journal-title":"Clin Exp Rheumatol"},{"key":"2282_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152313","volume":"64","author":"TA Simon","year":"2024","unstructured":"Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, et al. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024;64:152313.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR101","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"2282_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152312","volume":"64","author":"P-A Juge","year":"2024","unstructured":"Juge P-A, Hayashi K, McDermott GC, Vanni KMM, Kowalski E, Qian G, et al. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum. 2024;64:152312.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152710","volume":"72","author":"B Atienza-Mateo","year":"2025","unstructured":"Atienza-Mateo B, Serrano-Combarro A, Loarce Martos J, Vegas-Revenga N, Mart\u00edn L\u00f3pez M, Casta\u00f1eda S, et al. Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients. Semin Arthritis Rheum. 2025;72:152710.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103804","volume":"24","author":"J Narv\u00e1ez","year":"2025","unstructured":"Narv\u00e1ez J, Aguilar-Coll M, Roig-Kim M, Palacios-Olid J, Maym\u00f3-Paituvi P, de Daniel-Bisbe L, et al. Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2025;24:103804.","journal-title":"Autoimmun Rev"},{"key":"2282_CR105","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3899\/jrheum.2024-0976","volume":"52","author":"M Sebastiani","year":"2025","unstructured":"Sebastiani M, Lepri G, Iannone C, Cassione EB, Guggino G, Lo Monaco A, et al. Nintedanib in rheumatoid arthritis\u2013related interstitial lung disease: real-world safety profile and risk of side effects and discontinuation. J Rheumatol. 2025;52:420\u20135.","journal-title":"J Rheumatol"},{"key":"2282_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-025-03311-9","volume":"26","author":"MA Nieto","year":"2025","unstructured":"Nieto MA, Vadillo C, Pernaute OS, Romero-Bueno F, Rodriguez-Nieto MJ, Laporta R, et al. Role of antifibrotics in progressive pulmonary fibrosis associated to autoimmune diseases: multicenter study from NEREA registry. Respir Res. 2025;26:234.","journal-title":"Respir Res"},{"key":"2282_CR107","doi-asserted-by":"publisher","first-page":"182","DOI":"10.63032\/POPM9413","volume":"3","author":"AC Duarte","year":"2024","unstructured":"Duarte AC, Marques Gomes C, Correia M, Mendes B, Mazeda C, Guimar\u00e3es F, et al. Antifibrotics in rheumatoid arthritis-associated interstitial lung disease\u2014real-world data from a nationwide cohort. ARP Rheumatol. 2024;3:182\u20138.","journal-title":"ARP Rheumatol"},{"issue":"23","key":"2282_CR108","first-page":"7074","volume":"13","author":"J Narv\u00e1ez","year":"2024","unstructured":"Narv\u00e1ez J, Aguilar-Coll M, Vicens-Zygmunt V, Alegre JJ, Bermudo G, Molina-Molina M. Real-world clinical effectiveness and safety of antifibrotics in progressive pulmonary fibrosis associated with rheumatoid arthritis. J Clin Med. 2024;13(23):7074.","journal-title":"ARP Rheumatol"},{"key":"2282_CR109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","volume":"11","author":"JJ Solomon","year":"2023","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11:87\u201396.","journal-title":"Lancet Respir Med"},{"key":"2282_CR110","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold A-M, Kreuter M, et al. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392:2203\u201314.","journal-title":"N Engl J Med"},{"key":"2282_CR111","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392:2193\u2013202.","journal-title":"N Engl J Med"},{"key":"2282_CR112","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5680","volume":"254","author":"EH Budi","year":"2021","unstructured":"Budi EH, Schaub JR, Decaris M, Turner S, Derynck R. TGF-\u03b2 as a driver of fibrosis: physiological roles and therapeutic opportunities. J Pathol. 2021;254:358\u201373.","journal-title":"J Pathol"},{"key":"2282_CR113","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1111\/bph.17303","volume":"181","author":"D Reininger","year":"2024","unstructured":"Reininger D, Fundel-Clemens K, Mayr CH, Wollin L, Laemmle B, Quast K, et al. PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells. Br J Pharmacol. 2024;181:4766\u201381.","journal-title":"Br J Pharmacol"},{"key":"2282_CR114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","volume":"18","author":"F Luppi","year":"2022","unstructured":"Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18:85\u201396.","journal-title":"Nat Rev Rheumatol"},{"key":"2282_CR115","doi-asserted-by":"crossref","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194:265\u201375.","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2282_CR116","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","volume":"11","author":"A Manfredi","year":"2019","unstructured":"Manfredi A, Sebastiani M, Cerri S, Vacchi C, Tonelli R, Della Casa G, et al. Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Dis. 2019;11:1621\u20138.","journal-title":"J Thorac Dis"},{"key":"2282_CR117","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-022-01978-y","volume":"23","author":"H Hozumi","year":"2022","unstructured":"Hozumi H, Kono M, Hasegawa H, Kato S, Inoue Y, Suzuki Y, et al. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. Respir Res. 2022;23:57.","journal-title":"Respir Res"},{"key":"2282_CR118","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","volume":"51","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Ohbe H, Ikeda K, Uda K, Furuya H, Furuta S, et al. Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database. Semin Arthritis Rheum. 2021;51:977\u201382.","journal-title":"Semin Arthritis Rheum"},{"key":"2282_CR119","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003479","volume":"9","author":"F Le\u00f3n Rom\u00e1n","year":"2023","unstructured":"Le\u00f3n Rom\u00e1n F, Pintado-Cort B, Garc\u00eda-Casado D, Mu\u00f1iz-Gonz\u00e1lez F, L\u00f3pez Garc\u00eda-Asenjo JA, D\u00edaz-Rodr\u00edguez C, et al. Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease. RMD Open. 2023;9:e003479.","journal-title":"RMD Open"},{"key":"2282_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127771","volume":"10","author":"M Donahoe","year":"2015","unstructured":"Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS ONE. 2015;10:e0127771.","journal-title":"PLoS ONE"},{"key":"2282_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2024","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 2024;15:1519671.","journal-title":"Front Immunol"},{"key":"2282_CR122","doi-asserted-by":"publisher","first-page":"80","DOI":"10.14715\/cmb\/2025.71.6.11","volume":"71","author":"AV Blagov","year":"2025","unstructured":"Blagov AV, Pleshko EM, Maltseva ON, Asoyan AZ, Ravani AL, Orekhov AN. CAR-T cell therapy for rheumatoid arthritis: current status and molecular insights. Cell Mol Biol. 2025;71:80\u20138.","journal-title":"Cell Mol Biol"},{"key":"2282_CR123","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402:2034\u201344.","journal-title":"Lancet"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02282-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02282-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02282-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:31:08Z","timestamp":1772771468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02282-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02282-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MS, FL, and EB jointly determined the content of the manuscript. MS drafted the initial version, and FL and EB critically revised it. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}